Drugs / GM-2505
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06236880 | Jan 2024 → Oct 2026 expected | major depressive disorder | Gilgamesh Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GM-2505 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06236880 ↗ |